Effect of ivabradine on left ventricular diastolic function in patients with heart failure with preserved ejection fractio
- Conditions
- Heart failure with preserved ejection fraction
- Registration Number
- JPRN-UMIN000038225
- Lead Sponsor
- Kobe University Graduate School of Medicine
- Brief Summary
Primary end point No significant change was observed in E/e 3 months after administration of 5 mg/day of ivabradine from 12.1 +/- 4.4 at baseline to 13.6 +/- 4.1 (p=0.16). Secondary end point No significant changes were observed in BNP from 30.1 (9.2-85.0) pg/mL to 21.1 (11.7-154.2) pg/mL (p = 0.89) or LAVI from 38.7 +/- 17.5 mL/m2 to 44.0 +/- 17.1 mL/m2 (p=0.34). However, GLS significantly improved from 17.1 +/- 3.5% to 18.6 +/- 3.6% 3 months after administration of 5 mg/day of ivabradine (p=0.01).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 16
Not provided
(1) Patients with atrial fibrillation (2) Patients with sick sinus syndrome, interatrial block, third-degree atrioventricular block (3) Patients with hypotension (systolic blood pressure less than 90mmHg or diastolic blood pressure less than 50mmHg) (4) Patients with severe liver disease (Child-Pugh C) (4) Patients with hyperkalemia or serum potassium level>5.0mEq/L at enrollment (5) Patients erceiving Ritonavir pharmacokinetics, Josamycin, Itraconazole, Clarithromycin, Cobicistat, Indinavir, Voriconazole, Nelfinavir mesilate, Saquinavir, Telaprevir, Verapamil hydrochloride,Diltiazem hydrochloride (6) Pregnant women, lactating woman or women who wish to a pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A change in E/e' between baseline and 6 months after the start of administration of ivabradine
- Secondary Outcome Measures
Name Time Method A change in BNP (NT-proBNP) and left atrial volume index between baseline and 6 months after the start of administration of ivabradine